Asaduzzaman Asad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asaduzzaman Asad has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Zhahirul Islam
Gut Brain Axis Laboratory, Infectious Diseases Division, icddr,b, Dhaka, Bangladesh
11 shared publications - Shoma Hayat
Gut‐Brain Axis Laboratory, Infectious Diseases Division (IDD) icddr,b Dhaka Bangladesh
10 shared publications - Israt Jahan
Gut-Brain Axis Laboratory, Infectious Diseases Division, ICDDR, B
6 shared publications - Md. Abu Jaher Nayeem
Gut-Brain Axis Laboratory, Infectious Disease Division, icddr,b, Dhaka, Bangladesh
6 shared publications Ruma Begum
Gut-Brain Axis Laboratory, Infectious Disease Division, icddr,b, Dhaka, Bangladesh
6 shared publications- Golam Mostafa
Gut‐Brain Axis Laboratory, Infectious Diseases Division (IDD) icddr,b Dhaka Bangladesh
5 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Distinct gut microbial signatures associated with disease onset and clinical course in Guillain–Barre syndrome
- 5 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessDistinct gut microbial signatures associated with disease onset and clinical course in Guillain–Barre syndrome
- 11 July 2026
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 31 (3) , e70141
Impact of Gut Microbiota Dysbiosis in Treatment Outcomes of Guillain‐Barré Syndrome
Background and Aims: The gut‐microbiota plays a significant role in neuro‐autoimmune diseases, like Guillain‐Barré syndrome (GBS), a post‐infectious disorder of the peripheral nervous system (PNS). By altering host immunity, gut dysbiosis may impact the standard therapeutic efficacy of intravenous immunoglobulin (IVIg) and plasma exchange (PE) and thereby, disease progression in GBS. In this study, we investigated the impact of gut‐microbiota diversity on therapeutic outcomes of IVIg and PE in patients with GBS. Methods: We enrolled 60 patients with GBS categorized into three treatment groups: IVIg‐treated, PE, and supportive‐care along with 60 age‐sex‐matched healthy controls from Bangladesh. Fecal microbial DNA was extracted at different timepoints and sequenced. Clinical and sequenced data were analyzed using the Qiime2‐Dada2 pipeline. Results: Gut‐microbial diversity significantly differed in patients with GBS before and after treatment (Shannon: p = 0.037; Evenness: p = 0.012), particularly in IVIg‐treated patients, showing significant changes after 6‐month treatment (Shannon: p = 0.034; Evenness: p = 0.011). Beta diversity indicated microbiota restoration in IVIg‐treated patients toward a healthy state after treatment ( p ≤ 0.001). Phylum Actinobacteriota ( p = 0.026), genera Bifidobacterium ( p = 0.006), and Enterococcus ( p ≤ 0.0001) were relatively abundant in severe patients. Mechanically ventilated patients showed significant gut‐microbial diversity (Unweighted‐UniFrac; p ≤ 0.001). Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia‐Shigella , and Actinomyces in GBS patients. Interpretation: Our exploratory study indicates that gut microbiota dysbiosis is associated with GBS severity and IVIg‐treatment outcomes. IVIg‐treatment promoted partial restoration of microbial diversity, suggesting a potential immunomodulatory effect mediated through the microbiota. Further studies using meta‐transcriptomics are warranted to define functional consequences of microbial shifts in treatment responses of GBS.
- 11 July 2026
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 31 (3) , e70141
Impact of Gut Microbiota Dysbiosis in Treatment Outcomes of Guillain‐Barré Syndrome
Background and Aims: The gut‐microbiota plays a significant role in neuro‐autoimmune diseases, like Guillain‐Barré syndrome (GBS), a post‐infectious disorder of the peripheral nervous system (PNS). By altering host immunity, gut dysbiosis may impact the standard therapeutic efficacy of intravenous immunoglobulin (IVIg) and plasma exchange (PE) and thereby, disease progression in GBS. In this study, we investigated the impact of gut‐microbiota diversity on therapeutic outcomes of IVIg and PE in patients with GBS. Methods: We enrolled 60 patients with GBS categorized into three treatment groups: IVIg‐treated, PE, and supportive‐care along with 60 age‐sex‐matched healthy controls from Bangladesh. Fecal microbial DNA was extracted at different timepoints and sequenced. Clinical and sequenced data were analyzed using the Qiime2‐Dada2 pipeline. Results: Gut‐microbial diversity significantly differed in patients with GBS before and after treatment (Shannon: p = 0.037; Evenness: p = 0.012), particularly in IVIg‐treated patients, showing significant changes after 6‐month treatment (Shannon: p = 0.034; Evenness: p = 0.011). Beta diversity indicated microbiota restoration in IVIg‐treated patients toward a healthy state after treatment ( p ≤ 0.001). Phylum Actinobacteriota ( p = 0.026), genera Bifidobacterium ( p = 0.006), and Enterococcus ( p ≤ 0.0001) were relatively abundant in severe patients. Mechanically ventilated patients showed significant gut‐microbial diversity (Unweighted‐UniFrac; p ≤ 0.001). Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia‐Shigella , and Actinomyces in GBS patients. Interpretation: Our exploratory study indicates that gut microbiota dysbiosis is associated with GBS severity and IVIg‐treatment outcomes. IVIg‐treatment promoted partial restoration of microbial diversity, suggesting a potential immunomodulatory effect mediated through the microbiota. Further studies using meta‐transcriptomics are warranted to define functional consequences of microbial shifts in treatment responses of GBS.
- Open Access
- 25 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Molecular epidemiology of Campylobacter jejuni associated with Guillain–Barré syndrome
Campylobacter jejuni is the leading cause of bacterial gastroenteritis and its post-infectious sequelae, Guillain-Barré syndrome (GBS). Disease epidemiology of campylobacteriosis differs between high- and low-income countries. The molecular epidemiology of GBS-associated C. jejuni strains has not been thoroughly studied to understand its population dynamics and unique genomic features. We investigated a genome-based epidemiological analysis of 90 GBS-associated C. jejuni strains from 10 different countries to elucidate bacterial genomic features and epidemiological patterns related to GBS induction. We found 11 clonal complexes (CC) and 25 sequence types (STs) with two prevalent lineages, CC-362 (ST-2993) and CC-22(ST-22). SNP-based phylogenetic analysis revealed, the first sequenced C. jejuni (CC-22) from USA was genetically associated with strains from Bangladesh, Mexico, and China. Lipo-oligosaccharide (LOS) class A was prevalent worldwide (63%). In Bangladesh, 32% (9/28) of sialyltransferase cstII-genes harbored a Threonine at 51st-position, compared to China (60%, 6/10), USA (100%, 2/2), and Netherlands (67%, 4/6). Type-VI secretion system was enriched in Bangladesh (11/38, 29%). Among C. jejuni-integrated elements, CJIE-1 was most common (27/90, 30%). Phase variation was significantly higher in CC-403 strains. These diversified genomic characteristics of GBS-associated C. jejuni enhance our understanding of its pathogenic virulence features and linked epidemiological-pattern in Bangladesh and worldwide.
- 25 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessMolecular epidemiology of Campylobacter jejuni associated with Guillain–Barré syndrome
Campylobacter jejuni is the leading cause of bacterial gastroenteritis and its post-infectious sequelae, Guillain-Barré syndrome (GBS). Disease epidemiology of campylobacteriosis differs between high- and low-income countries. The molecular epidemiology of GBS-associated C. jejuni strains has not been thoroughly studied to understand its population dynamics and unique genomic features. We investigated a genome-based epidemiological analysis of 90 GBS-associated C. jejuni strains from 10 different countries to elucidate bacterial genomic features and epidemiological patterns related to GBS induction. We found 11 clonal complexes (CC) and 25 sequence types (STs) with two prevalent lineages, CC-362 (ST-2993) and CC-22(ST-22). SNP-based phylogenetic analysis revealed, the first sequenced C. jejuni (CC-22) from USA was genetically associated with strains from Bangladesh, Mexico, and China. Lipo-oligosaccharide (LOS) class A was prevalent worldwide (63%). In Bangladesh, 32% (9/28) of sialyltransferase cstII-genes harbored a Threonine at 51st-position, compared to China (60%, 6/10), USA (100%, 2/2), and Netherlands (67%, 4/6). Type-VI secretion system was enriched in Bangladesh (11/38, 29%). Among C. jejuni-integrated elements, CJIE-1 was most common (27/90, 30%). Phase variation was significantly higher in CC-403 strains. These diversified genomic characteristics of GBS-associated C. jejuni enhance our understanding of its pathogenic virulence features and linked epidemiological-pattern in Bangladesh and worldwide.
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@JP]!飛鳥ハーフマラソン2026 放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@JP]!飛鳥ハーフマラソン2026 放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@TV]! 飛鳥ハーフマラソン2026放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@TV]! 飛鳥ハーフマラソン2026放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@TV]! 飛鳥ハーフマラソン2026放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@TV]! 飛鳥ハーフマラソン2026放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@TV]! 飛鳥ハーフマラソン2026放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 7 March 2026
- Published by ResearchHub Technologies, Inc.
[放送@TV]! 飛鳥ハーフマラソン2026放送・ライブ放送・ライブ放送・生中継・テレビ放送・ライブ配信・生放送 2026年03月08日
- 6 March 2026
- Published by ResearchHub Technologies, Inc.
![ROJADIRECTA]! Napoli - Torino In Diretta Gratis 06 marzo 2026
- 6 March 2026
- Published by ResearchHub Technologies, Inc.
![ROJADIRECTA]! Napoli - Torino In Diretta Gratis 06 marzo 2026
- 6 March 2026
- Published by ResearchHub Technologies, Inc.
HD√{WBC2026放送}侍ジャパン vs チャイニーズライブ放送, テレビ放送 ライブ配信 2026年03月06日
- 6 March 2026
- Published by ResearchHub Technologies, Inc.
HD√{WBC2026放送}侍ジャパン vs チャイニーズライブ放送, テレビ放送 ライブ配信 2026年03月06日